10-Q: Cannabis Bioscience International Holdings Reports Q3 2025 Results: Revenue Increase Offset by Continued Losses

Cannabis Bioscience International Holdings reports increased revenue for the nine months ended February 28, 2025, but continues to struggle with net losses and a going concern uncertainty.

Summary

• Cannabis Bioscience International Holdings, Inc. reported its financial results for the quarter and nine months ended February 28, 2025.
• The company's revenue increased to $268,066 for the nine months ended February 28, 2025, compared to $172,979 for the same period in 2024.
• However, the company experienced a net loss of $337,076 for the nine months ended February 28, 2025, although this is an improvement compared to the $515,410 loss in the prior year.
• The company's operating loss decreased from $456,506 to $298,575 year-over-year.
• The report indicates a 'substantial doubt' about the company's ability to continue as a going concern due to recurring losses and negative cash flows.
• As of February 28, 2025, the company had $548 in cash and cash equivalents and a negative working capital of $887,716.
• The company issued 425,000,000 shares of common stock for cash, raising $120,500 during the quarter.
• The company's disclosure controls and procedures were deemed ineffective as of February 28, 2025.

Sentiment

Score: 4

Explanation: The sentiment is negative due to the going concern warning and continued losses, despite some revenue growth. The ineffective disclosure controls also raise concerns.

Positives

• Revenue increased significantly for the nine months ended February 28, 2025, driven by clinical trials.
• The net loss decreased compared to the same period in the previous year.
• Operating loss decreased compared to the same period in the previous year.
• Total operating expenses decreased due to reductions in contract labor and professional fees.

Negatives

• The company continues to experience net losses and negative cash flows from operating activities.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company has a negative working capital of $887,716 as of February 28, 2025.
• Disclosure controls and procedures were deemed ineffective as of February 28, 2025.

Risks

• The company's ability to continue as a going concern is uncertain due to recurring losses and negative cash flows.
• The company needs additional capital to fund its business and repay its debts.
• There is no assurance that the company will be able to obtain additional capital on satisfactory terms.
• Ineffective disclosure controls and procedures could lead to inaccurate financial reporting.

Future Outlook

The company's ability to continue as a going concern depends on the successful execution of its operating plan, which includes increasing sales of existing services and introducing new services, as well as raising either debt or equity financing.

Industry Context

The company operates in the cannabis and clinical research industries, both of which are subject to evolving regulations and competitive pressures. The company's focus on medical cannabis education and clinical trials positions it to capitalize on the growing interest in cannabinoid-based therapies.

Comparison to Industry Standards

• It is difficult to compare Cannabis Bioscience International Holdings directly to industry standards due to its unique combination of cannabis education and clinical trial services.
• However, other companies in the cannabis industry, such as Canopy Growth Corporation and Aurora Cannabis, have faced similar challenges with profitability and cash flow management.
• Clinical research organizations (CROs) like IQVIA and Labcorp typically have more stable revenue streams and stronger balance sheets than Cannabis Bioscience International Holdings.

Related Party Transactions

• During the nine months ended February 28, 2025, and the year ended May 31, 2024, the Company received cash advances from related parties of and $81,552 and $218,504 for use as working capital.
• The balance of related party liabilities owed to certain shareholders totaled $584,766 and $503,214 at February 28, 2025, and May 31, 2024, respectively.
• On April 26, 2024, the Company made a promissory note in the principal amount of $291,451 in favor of a related party.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern uncertainty.
• Employees may be affected by potential cost-cutting measures or even termination of operations.
• Customers may be impacted by the company's ability to deliver services and products.
• Creditors face increased risk of non-payment due to the company's financial difficulties.

Key Dates

Keywords

financial results, cannabis, clinical trials, revenue, net loss, going concern, bioscience